StockData
Aura Biosciences, Inc. logo

Aura Biosciences, Inc. (AURA) shareholders

AURANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30
$7.15−0.07 (-0.97%)

Close on Nov 17, 2026Market cap $741.49MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
94.8%
98M of 104M shares
Institutional holders
146
37 new, 15 sold out
Net institutional buying
47M
In Q2 2026
Insider trades, 12 months
0 buys · 11 sales
Net sold $39.95M

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Chen Yu
Joint filing with TCG Crossover GP II, LLC (5.00%), TCG Crossover Fund II, L.P. (5.00%) and 2 more
9,533,3339.90%13G (passive)May 5, 2026
Robert Atchinson
Joint filing with Adage Capital Management, L.P. (8.44%), Phillip Gross (8.44%)
9,104,2948.44%13G (passive) amendmentJun 30, 2026
Matrix Capital Management Company LP
Joint filing with David E. Goel (11.17%)
6,922,87011.17%13D (active) amendmentMay 16, 2025
Patrick J. Heron
Joint filing with James N. Topper (9.90%), Albert Cha (7.90%) and 4 more
6,315,6789.90%13G (passive)May 16, 2025
Frazier Life Sciences Public Fund, L.P.
Joint filing with Fhmlsp, L.P. (5.60%), Fhmlsp, L.L.C. (5.60%)
5,807,2605.60%13G (passive) amendmentJun 30, 2026
ForGrowth III PA B.V.
Joint filing with Forbion Growth Opportunities Fund III Cooperatief U.A. (5.10%), Forbion Growth III Management B.V. (5.10%)
5,248,8415.10%13G (passive)Sep 25, 2026
BlackRock, Inc.5,219,4925.03%13G (passive)Sep 30, 2026
Suvretta Capital Management, LLC
Joint filing with Aaron Cowen (7.60%), Averill Master Fund, Ltd. (6.60%)
4,701,7757.60%13G (passive) amendmentJun 30, 2025
Adage Capital Partners GP, L.L.C.
Joint filing with Adage Capital Partners, L.P. (8.61%), Adage Capital Management, L.P. (8.61%) and 2 more
4,225,0008.61%13G (passive) amendmentDec 31, 2023
Fhmlsp, L.P.
Joint filing with Frazier Life Sciences Public Fund, L.P. (6.30%), Fhmlsp, L.L.C. (6.30%)
4,032,0606.30%13G (passive) amendmentDec 31, 2025
Long Focus Capital Management, LLC
Joint filing with John Helmers (6.60%)
3,319,5826.60%13G (passive) amendmentMar 31, 2025
Fhmlsp, L.L.C.
Joint filing with Frazier Life Sciences Public Fund, L.P. (5.00%), Fhmlsp, L.P. (5.00%)
3,113,5505.00%13G (passive) amendmentJun 30, 2025
Aaron Cowen
Joint filing with Suvretta Capital Management, LLC (6.10%), Averill Master Fund, Ltd. (5.40%)
3,057,3196.10%13G (passive)Apr 4, 2025

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of AURAValueChange% of portfolio
TCG Crossover Management, LLC9,533,3339.19%$67.69MNew1.63%
Suvretta Capital Management, LLC7,206,2176.95%$51.16M+2,833,3330.94%
Frazier Life Sciences Management, L.P.7,100,0006.85%$50.41M+2,000,0001.10%
Nantahala Capital Management, LLC5,902,0605.69%$41.90M+3,784,3630.70%
Long Focus Capital Management, LLC5,119,5824.94%$36.35M+500,0000.93%
BlackRock, Inc.4,707,6744.54%$33.42M+1,121,0340.00%
Adage Capital Partners Gp, L.L.C.4,640,0004.47%$32.94M−241,1250.05%
Caligan Partners LP4,298,2484.14%$30.52M+4,068,3841.44%
Vanguard Capital Management LLC4,100,3423.95%$29.11M+1,856,5140.00%
Fcpm Iii Services B.V.4,053,7753.91%$28.78MNew3.84%
Orbimed Advisors LLC3,333,3333.21%$23.67MNew0.44%
Medicxi Ventures Management (Jersey) Ltd3,039,8922.93%$21.58M–12.16%
Jupiter Topco LLC2,500,0002.41%$17.79MNew0.01%
Ra Capital Management, L.P.2,500,0002.41%$17.75MNew0.15%
Balyasny Asset Management L.P.2,354,6192.27%$16.72M+1,796,9650.02%
Franklin Resources Inc2,072,7262.00%$14.72M–0.00%
Geode Capital Management, LLC1,754,7211.69%$12.46M+443,8590.00%
Redmile Group, LLC1,666,6671.61%$11.83MNew0.79%
EcoR1 Capital, LLC1,666,6671.61%$11.83MNew0.58%
Trails Edge Capital Partners, LP1,443,3331.39%$10.25MNew1.63%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 202614698M94.8%37 / 5827 / 1556M8M
Q1 202612651M49.1%23 / 3941 / 125M1M
Q4 202511750M48.4%19 / 3438 / 81M3M
Q3 202510652M49.8%15 / 3426 / 132M1M
Q2 202510451M48.8%26 / 3230 / 1512M1M
Q1 20259440M38.4%15 / 3129 / 145M5M
Q4 20249439M38.0%22 / 3816 / 95M2M
Q3 20248137M35.6%11 / 3025 / 34M5M
Q2 20247541M39.6%12 / 3519 / 154M3M
Q1 20247839M37.9%13 / 3419 / 73M2M
Q4 20237238M37.0%16 / 3710 / 713M1M
Q3 20236427M26.5%6 / 2619 / 11M1M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

135 funds held AURA in Q2 2026, 68% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of AURAValue% of fundAs of
Vanguard Total Stock Market Index Fund2,902,2922.80%$20.61M0.00%Jun 30, 2026
iShares Russell 2000 ETF1,171,1911.13%$8.32M0.01%Jun 30, 2026
Vanguard Extended Market Index Fund1,108,2121.07%$7.87M0.01%Jun 30, 2026
Franklin Biotechnology Discovery Fund765,6170.74%$5.37M0.46%Jul 31, 2026
Fidelity Extended Market Index Fund502,3970.48%$3.75M0.01%May 31, 2026
Fidelity Small Cap Index Fund488,9200.47%$3.43M0.01%Jul 31, 2026
iShares Biotechnology ETF455,9720.44%$3.24M0.04%Jun 30, 2026
iShares Russell 2000 Growth ETF394,3960.38%$2.80M0.02%Jun 30, 2026
Vanguard Health Care Index Fund279,3370.27%$2.09M0.01%May 31, 2026
Vanguard Russell 2000 Index Fund231,0860.22%$1.73M0.01%May 31, 2026
Fidelity Enhanced Small Cap Core ETF196,0670.19%$1.39M0.02%Jun 30, 2026
Vanguard Explorer Fund187,0480.18%$1.31M0.01%Jul 31, 2026
Fidelity Total Market Index Fund183,0890.18%$1.37M0.00%May 31, 2026
iShares Core S&P Total U.S. Stock Market ETF181,3590.17%$1.29M0.00%Jun 30, 2026
Dimensional U.S. Small Cap ETF174,9070.17%$1.23M0.01%Jul 31, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Natalie C. HollesSee Remarks, Director600,1180.58%May 19, 2026
los Pinos Elisabet deSee Remarks, Director703,5780.68%Mar 3, 2026
Janet Jill HopkinsChief Medical Officer363,2870.35%Nov 16, 2026
Julie PersonChief People Officer107,6110.10%Sep 1, 2026
Susan Abu-AbsiChief Operating Officer134,5130.13%Sep 1, 2026
Erica KratzChief Reg. & Quality Officer100,8850.10%Sep 1, 2026
Amy ElazzouziSVP, Finance & PAO143,6000.14%Sep 1, 2026
Conor KilroySee Remarks232,6930.22%Jul 1, 2026
Anthony S. GibneySee Remarks265,3540.26%Jun 16, 2026
Mark PlavsicChief Technology Officer243,7360.24%Mar 3, 2026
Jeremy BenderDirector30,0000.03%Jul 8, 2026
Sapna SrivastavaDirector38,5000.04%Jun 15, 2026
Teresa Marie BitettiDirector36,0000.03%Jun 15, 2026
Antony C. MattessichDirector38,5000.04%Jun 15, 2026
David Michael JohnsonDirector483,8390.47%Jun 15, 2026
Matrix Capital Management Company, LP10% owner0–May 11, 2026
David E. Goel10% owner4,112,8703.97%May 11, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Janet Jill Hopkins
Chief Medical Officer
Nov 16, 2026Sale−16,903$7.05$119.17K363,287
Erica Kratz
Chief Reg. & Quality Officer
Sep 1, 2026Award+100,885––100,885
Janet Jill Hopkins
Chief Medical Officer
Sep 1, 2026Award+58,850––380,190
Susan Abu-Absi
Chief Operating Officer
Sep 1, 2026Award+134,513––134,513
Julie Person
Chief People Officer
Sep 1, 2026Award+107,611––107,611
Amy Elazzouzi
SVP, Finance & PAO
Sep 1, 2026Award+23,540––143,600
Jeremy Bender
Director
Jul 7, 2026Award+30,000––30,000
Conor Kilroy
See Remarks
Jul 1, 2026Award+14,858––232,693
Anthony S. Gibney
See Remarks
Jun 16, 2026Sale−12,824$6.42$82.33K265,354
Teresa Marie Bitetti
Director
Jun 11, 2026Award+15,000––36,000
Antony C. Mattessich
Director
Jun 11, 2026Award+15,000––38,500
David Michael Johnson
Director
Jun 11, 2026Award+15,000––194,167
Sapna Srivastava
Director
Jun 11, 2026Award+15,000––38,500
Natalie C. Holles
See Remarks, Director
May 19, 2026Award+600,118––600,118
Natalie C. Holles
See Remarks, Director
May 19, 2026Award+553,844––1,153,962
Matrix Capital Management Company, LP
10% owner
May 7, 2026Sale−6,922,870$5.64$39.04M0
Conor Kilroy
See Remarks
Apr 16, 2026Sale−11,738$7.02$82.40K217,835
Conor Kilroy
See Remarks
Mar 2, 2026Award+62,339––229,573
los Pinos Elisabet de
See Remarks, Director
Mar 2, 2026Award+166,000––575,815
Mark Plavsic
Chief Technology Officer
Mar 2, 2026Award+62,339––243,736
Janet Jill Hopkins
Chief Medical Officer
Mar 2, 2026Award+89,056––321,340
Anthony S. Gibney
See Remarks
Mar 2, 2026Award+71,245––278,178
Amy Elazzouzi
Senior Vice President, Finance
Mar 2, 2026Award+44,528––120,060
los Pinos Elisabet de
See Remarks, Director
Feb 17, 2026Sale−47,648$5.06$241.10K409,815
Conor Kilroy
See Remarks
Feb 17, 2026Sale−12,079$5.05$61.00K167,234
Amy Elazzouzi
Senior Vice President, Finance
Feb 17, 2026Sale−8,549$5.06$43.26K75,532
Janet Jill Hopkins
Chief Medical Officer
Feb 17, 2026Sale−20,401$5.06$103.23K232,284
Mark Plavsic
Chief Technology Officer
Feb 17, 2026Sale−15,890$5.05$80.24K181,397
los Pinos Elisabet de
See Remarks, Director
Jan 20, 2026Sale−16,928$4.86$82.27K457,463
Amy Elazzouzi
Senior Vice President, Finance
Jan 20, 2026Sale−1,581$4.86$7.68K84,081
Janet Jill Hopkins
Chief Medical Officer
Nov 17, 2025Sale−17,109$5.42$92.73K252,685
Amy Elazzouzi
Senior Vice President, Finance
Oct 29, 2025Sale−896$6.35$5.69K85,662
los Pinos Elisabet de
See Remarks, Director
Oct 29, 2025Sale−9,049$6.35$57.46K474,391
Mark Plavsic
Chief Technology Officer
Oct 16, 2025Sale−12,169$6.35$77.27K197,287
Amy Elazzouzi
Senior Vice President, Finance
Aug 18, 2025Option exercise+1,094$3.16$3.46K91,961
Amy Elazzouzi
Senior Vice President, Finance
Aug 18, 2025Option exercise+2,554$5.07$12.95K83,935
Amy Elazzouzi
Senior Vice President, Finance
Aug 18, 2025Sale−7,722$6.70$51.74K86,558
Amy Elazzouzi
Senior Vice President, Finance
Aug 18, 2025Option exercise+4,744$2.74$13.00K90,867
Amy Elazzouzi
Senior Vice President, Finance
Aug 18, 2025Option exercise+547$5.48$3.00K85,576
Amy Elazzouzi
Senior Vice President, Finance
Aug 18, 2025Option exercise+547$5.21$2.85K86,123
Amy Elazzouzi
Senior Vice President, Finance
Aug 18, 2025Option exercise+1,094$5.48$6.00K85,029
Amy Elazzouzi
Senior Vice President, Finance
Aug 18, 2025Option exercise+2,319$4.25$9.86K94,280
Antony C. Mattessich
Director
Jun 17, 2025Award+13,000––23,500
David Michael Johnson
Director
Jun 17, 2025Award+13,000––179,167
Sapna Srivastava
Director
Jun 17, 2025Award+13,000––23,500
los Pinos Elisabet de
See Remarks, Director
Jun 2, 2025Tax withholding−9,948$6.16$61.28K483,440
los Pinos Elisabet de
See Remarks, Director
Jun 2, 2025Option exercise+10,948$5.07$55.51K493,388
Anthony S. Gibney
See Remarks
Jun 2, 2025Award+150,000––206,933
David Michael Johnson
Director
May 16, 2025Buy+20,000$4.90$98.00K166,167
Anthony S. Gibney
See Remarks
May 16, 2025Sale−1,519$5.15$7.82K56,933
Anthony S. Gibney
See Remarks
May 16, 2025Buy+50,000$4.90$245.00K58,452
Amy Elazzouzi
Senior Vice President, Finance
Apr 16, 2025Sale−897$5.49$4.92K81,381
Conor Kilroy
See Remarks
Apr 16, 2025Sale−7,162$5.49$39.32K179,313
Teresa Marie Bitetti
Director
Mar 31, 2025Award+21,000––21,000
Amy Elazzouzi
Senior Vice President, Finance
Feb 18, 2025Sale−1,404$7.75$10.88K82,278
los Pinos Elisabet de
See Remarks, Director
Feb 18, 2025Sale−20,221$7.75$156.71K482,440
Mark Plavsic
Chief Technology Officer
Feb 18, 2025Sale−2,151$7.75$16.67K209,456
Janet Jill Hopkins
Chief Medical Officer
Feb 18, 2025Sale−2,534$7.75$19.64K269,794
Amy Elazzouzi
Senior Vice President, Finance
Feb 3, 2025Award+45,240––83,682
Mark Plavsic
Chief Technology Officer
Feb 3, 2025Award+90,475––211,607

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
10.89%
10M shares short
Days to cover
13.7
At 1M shares a day
Change since last report
-3.9%
From 11M shares
Short volume, 20 days
53.4%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Aura Biosciences's stock actually held short. Settlement fails (shares not delivered on time) peaked at 8,026 shares on Oct 14, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
Anthony S. Gibney
Officer
Jun 16, 202612,824$82.33KJun 16, 2026Restricted Stock unit award granted pursuant to the Issuer's 2021 Stock Option and Incentive Plan, subject to vesting requirements.
Conor Kilroy
Officer
Apr 16, 202611,738$82.40KApr 16, 2026Restricted Stock unit award granted pursuant to the Issuer's 2021 Stock Option and Incentive Plan, subject to vesting requirements.
Mark Plavsic
Officer
Feb 17, 202615,890$80.27KFeb 17, 2026Restricted Stock unit award granted pursuant to the Issuer's 2021 Stock Option and Incentive Plan, subject to vesting requirements.
Conor Kilroy
Officer
Feb 17, 202612,079$61.04KFeb 17, 2026Restricted Stock unit award granted pursuant to the Issuer's 2021 Stock Option and Incentive Plan, subject to vesting requirements.
Janet Jill Hopkins
Officer
Feb 17, 202620,401$103.23KFeb 17, 2026Restricted Stock unit award granted pursuant to the Issuer's 2021 Stock Option and Incentive Plan, subject to vesting requirements.
los Pinos Elisabet de
Officer, Director
Feb 17, 202647,648$241.06KFeb 17, 2026Restricted Stock unit award granted pursuant to the Issuer's 2021 Stock Option and Incentive Plan, subject to vesting requirements.
Amy Elazzouzi
Officer
Feb 17, 20268,549$43.26KFeb 17, 2026Restricted Stock unit award granted pursuant to the Issuer's 2021 Stock Option and Incentive Plan, subject to vesting requirements.
Amy Elazzouzi
Officer
Jan 20, 20261,581$7.68KJan 20, 2026Restricted Stock unit award granted pursuant to the Issuer's 2021 Stock Option and Incentive Plan, subject to vesting requirements.
los Pinos Elisabet de
Officer, Director
Jan 20, 202616,928$82.23KJan 20, 2026Restricted Stock unit award granted pursuant to the Issuer's 2021 Stock Option and Incentive Plan, subject to vesting requirements.
Janet Jill Hopkins
Officer
Nov 17, 202517,109$92.73KNov 17, 2025Restricted Stock unit award granted pursuant to the Issuer's 2021 Stock Option and Incentive Plan, subject to vesting requirements.
Amy Elazzouzi
Officer
Oct 29, 2025896$5.69KOct 29, 2025Restricted Stock unit award granted pursuant to the Issuer's 2021 Stock Option and Incentive Plan, subject to vesting requirements.
los Pinos Elisabet de
Officer, Director
Oct 29, 20259,049$57.46KOct 29, 2025Restricted Stock unit award granted pursuant to the Issuer's 2021 Stock Option and Incentive Plan, subject to vesting requirements.
Mark Plavsic
Officer
Oct 16, 202512,169$77.27KOct 16, 2025Restricted Stock unit award granted pursuant to the Issuer's 2021 Stock Option and Incentive Plan, subject to vesting requirements.
Amy Elazzouzi
Officer
Aug 18, 20257,722$51.75KAug 18, 2025Stock Option Exercise
Anthony S. Gibney
Officer
May 16, 20251,519$7.82KMay 16, 2025Restricted Stock unit award granted pursuant to the Issuer's 2021 Stock Option and Incentive Plan, subject to vesting requirements.

See a number that looks wrong?